GlaxoSmithKline (NYSE:GSK) won FDA approval for the use of its Arnuity Ellipta inhaler as a once-daily therapy for the maintenance treatment of asthma in children as young as five years old. The pharmaceutical company touted its regulatory win, pointing out that the fluticasone furoate treatment is one of the only once-daily asthma therapies cleared in the […]
ResMed touts cost efficiency in home oxygen, non-invasive ventilation therapy study
ResMed (NYSE:RMD) today released data from two clinical analyses exploring combined home oxygen therapy and non-invasive ventilation therapy for patients with persistent hypercapnia following a life-threatening exacerbation of chronic obstructive pulmonary disorder, touting an increase in cost efficiency with the combined therapy. Results from the two studies, performed in the U.K. and the US, were presented […]
GlaxoSmithKline touts long-term study of biologic treatment for severe eosinophilic asthma
GlaxoSmithKline (NYSE:GSK) touted new data today from a long-term study of its biologic treatment for patients with severe eosinophilic asthma. One-third of patients treated with mepolizumab experienced no exacerbations, GSK reported – down from an average of two exacerbations each year at the start of the study. Get the full story at our sister site, Drug […]
Auris Health, Ethicon’s NeuWave ink robot-assisted bronchoscope ablation dev deal
Auris Health, previously known as Auris Surgical Robotics, said today it inked a cooperative development and commercialization deal with Johnson & Johnson (NYSE:JNJ) division Ethicon’s NeuWave Medical subsidiary looking to develop systems for the robotically-assisted bronchoscopic ablation of lung lesions. Through the agreement, both companies will help develop an integrated system for robotic control, navigation and […]
Inspire Medical prices up-sized $108m IPO
Inspire Medical Systems yesterday up-sized its initial public offering to $108 million, or some $124 million if the underwriters option is exercised in full. Maple Grove, Minn.-based Inspire, which spun out from Medtronic (NYSE:MDT) in 2007, makes devices for treating obstructive sleep apnea. The company had said it planned to issue 5 million shares at $14 to $16 apiece, […]
Body Vision Medical wins FDA nod for LungVision lung nav cath
Body Vision Medical said today it won FDA clearance for its LungVision lung navigation catheter. The Israel-based company said its LungVision catheter is designed for use in conjunction with standard bronchoscopes and its LungVision system for guiding endotherapy accessories to small pulmonary modules. “Body Vision has pioneered a new generation platform for navigation bronchoscopy that […]
Vyaire Medical acquires Acutronic, inks deal to acquire IMTmedical
Vyaire Medical said yesterday it acquired neonatal ventilation equipment developer Acutronic for an undisclosed amount, and said it inked a deal to acquire mechanical ventilation dev IMTmedical. Both of the new acquisitions are based in Europe, with Acutronic split between Switzerland and Germany and IMTmedical based solely in Switzerland, Chicago-based Vyaire Medical said. “The transactions […]
Theravance Biopharma touts expanded FDA nod for GSK’s Trelegy Ellipta inhaler
Theravance Biopharma‘s (NSDQ:TBPH) said today that the FDA granted expanded indications for GlaxoSmithKline‘s (NYSE:GSK) Trelegy Ellipta inhaler, now approved for use to treat a broader population of chronic obstructive pulmonary disease patients. With the expansion, the inhaler is now cleared for COPD patients with airflow limitations and for those who have experienced an acute worsening of […]
Medtronic spinout Inspire Medical sets range for $75m IPO
Inspire Medical Systems this week set the range for a proposed initial public offering that would fetch $75 million at the midpoint. Maple Grove, Minn.-based Inspire, which spun out from Medtronic (NYSE:MDT) in 2007, makes devices for treating obstructive sleep apnea. The company said it plans to issue 5 million shares at $14 to $16 apiece, setting its […]
AstraZeneca inks outcomes-based contract with Highmark for COPD, asthma drug
Health insurer Highmark inked an outcomes-based contract with AstraZeneca (NYSE:AZN) for Symbicort, the pharmaceutical company’s drug designed to treat asthma and chronic obstructive pulmonary disease. Highmark said its contract with AstraZeneca is one of the first outcomes-based deals involving a respiratory drug and will apply to commercial members of its national and core markets in Pennsylvania, […]
Study: Propeller’s digital asthma tech informs policy, improves health
Results from a large, real-world study of asthma patients found that digital health technology can improve patient outcomes and inform city-planning policy, Propeller Health touted this month. The company teamed up with local government in Louisville, Kentucky and a nonprofit group to assess how environmental conditions can influence asthma symptoms using connected inhalers and a data-sharing platform. […]
- 1
- 2
- 3
- …
- 47
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
Google+